Jak bezpiecznie prowadzić terapię marihuaną leczniczą? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2024
Słowa kluczowe:
medyczna marihuana, terapia, działania niepożądane
##plugins.themes.bootstrap3.article.main##
Abstrakt
Niniejsza praca stanowi przybliżenie kanadyjskiego opracowania, które ukazało się 3 lata temu na łamach „European Journal of Internal Medicine”. Omówiono w nim zasady prowadzenia i monitorowania terapii marihuaną medyczną. Przedstawiono informacje o działaniach niepożądanych, metodach dawkowania, doborze substancji czynnych i modyfikowaniu leczenia.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sapilak, B. J. (2024). Jak bezpiecznie prowadzić terapię marihuaną leczniczą? . Medycyna Faktów , 17(2(63), 174-178. https://doi.org/10.24292/01.MF.0224.01
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. MacCallum CA, Lo LA, Boivin M. “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations. Eur J Intern Med. 2021; 89: 10-8. https://doi.org/10.1016/j.ejim.2021.05.002.
2. Mechoulam R, Peters M, Murillo-Rodriguez E et al. Cannabidiol-recent advances. Chem Biodivers. 2007; 4(8): 1678-92.
3. Pisanti S, Malfitano AM, Ciaglia E et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175: 133-50.
4. Devinsky O, Marsh E, Friedman D et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016; 15(3): 270-8.
5. Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017; 72: 310-24.
6. Bergamaschi MM, Queiroz RH, Chagas MH et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011; 36: 1219-26.
7. MacCallum CA, Lo LA, Betts F et al. Chapter 31: product safety and quality control. Cannabinoids and Pain. Springer US, 2021. https://doi.org/10.1007/978- 3-030-69186-8_31.
8. Abuhasira R, Schleider LB-L, Mechoulam R et al Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Internal Med. 2018; 49: 44-50. https://doi.org/10.1016/j.ejim.2018.01.019.
9. Rein JL. The nephrologistis guide to cannabis and cannabinoids. Curr Opin Nephrol. Hypertens 2020; 29(2): 248-57. https://doi.org/10.1097/MNH.0000000000000590.
10. Layden JE, Ghinai I, Pray I et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin – preliminary report. N Engl J Med. 2020; 382(10): 903-16. https://doi.org/10.1056/NEJMoa1911614.
11. Eadie L, Lo LA, Christiansen A et al. Duration of neurocognitive impairment with medical cannabis use: a scoping review. Front Psychiatry 2021; Mar 12. https://doi.org/10.3389/fpsyt.2021.638962.
12. Atsmon J , Heffetz D, Deutsch L et al. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. Clinical Pharmacology in Drug Development. 2017; 00(0): 1-8. https://doi.org/10.1002/cpdd.408.
2. Mechoulam R, Peters M, Murillo-Rodriguez E et al. Cannabidiol-recent advances. Chem Biodivers. 2007; 4(8): 1678-92.
3. Pisanti S, Malfitano AM, Ciaglia E et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175: 133-50.
4. Devinsky O, Marsh E, Friedman D et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016; 15(3): 270-8.
5. Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017; 72: 310-24.
6. Bergamaschi MM, Queiroz RH, Chagas MH et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011; 36: 1219-26.
7. MacCallum CA, Lo LA, Betts F et al. Chapter 31: product safety and quality control. Cannabinoids and Pain. Springer US, 2021. https://doi.org/10.1007/978- 3-030-69186-8_31.
8. Abuhasira R, Schleider LB-L, Mechoulam R et al Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Internal Med. 2018; 49: 44-50. https://doi.org/10.1016/j.ejim.2018.01.019.
9. Rein JL. The nephrologistis guide to cannabis and cannabinoids. Curr Opin Nephrol. Hypertens 2020; 29(2): 248-57. https://doi.org/10.1097/MNH.0000000000000590.
10. Layden JE, Ghinai I, Pray I et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin – preliminary report. N Engl J Med. 2020; 382(10): 903-16. https://doi.org/10.1056/NEJMoa1911614.
11. Eadie L, Lo LA, Christiansen A et al. Duration of neurocognitive impairment with medical cannabis use: a scoping review. Front Psychiatry 2021; Mar 12. https://doi.org/10.3389/fpsyt.2021.638962.
12. Atsmon J , Heffetz D, Deutsch L et al. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. Clinical Pharmacology in Drug Development. 2017; 00(0): 1-8. https://doi.org/10.1002/cpdd.408.